BRANFORD, Conn. / Feb 13, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, and several distinguished researchers will highlight advances in Next-Generation Protein Sequencing™ (NGPS™) at the US Human Proteome Organization’s 2025 conference in Philadelphia, Pennsylvania through a panel discussion and multiple poster presentations.
Sponsored Panel Discussion: Breaking Boundaries in Proteomics
Quantum-Si is sponsoring and moderating the panel event “Breaking Boundaries: How Next-Generation Protein Sequencing™ is Shaping the Future of Proteomics” on February 25 from 12:30-1:30 PM ET. The session will provide an overview of the latest research leveraging Quantum-Si’s Platinum® Pro benchtop instrument, including a pioneering protein barcoding kit for sample multiplexing and a new library preparation solution for lower sample input.
Following the presentation, Dr. Benjamin Garcia (Washington University in St. Louis), Dr. Stephanie Cologna (University of Illinois Chicago), and Dr. John Prensner (University of Michigan) will engage in a discussion on the transformative impact of NGPS on proteomics, its role in overcoming existing challenges, and its integration with complementary technologies.
Scientific Posters Highlighting NGPS Innovation
Protein Sequencing with Single Amino Acid Resolution Discerns Myopathy-linked Regions in Tropomyosin Peptidoforms
Reducing Protein Input for Next-Generation Protein Sequencing on the Platinum Instrument
Accurate Measurement of Peptide Variant Mixtures with Next-Generation Protein Sequencing
Protein Barcoding and Next-Generation Protein Sequencing for Multiplexed Protein Selection, Analysis and Tracking
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® line of instruments enables Next-Gen Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.
Last Trade: | US$1.18 |
Daily Change: | 0.005 0.43 |
Daily Volume: | 4,041,768 |
Market Cap: | US$163.310M |
February 18, 2025 January 28, 2025 January 13, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load